CLINICAL TRIALS PROFILE FOR CABOTEGRAVIR SODIUM

All Clinical Trials for CABOTEGRAVIR SODIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02345707 ↗	Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir	Completed	ViiV Healthcare	Phase 1	2015-03-01	This study is a single-center, randomized, open-label, two cohorts, 3-way cross-over design in 36 subjects to assess the oral bioavailability of four new cabotegravir (CAB) sodium salt tablet formulations relative to the current CAB sodium salt formulation being used in the phase IIb studies under fasting conditions. All treatments will be administered as single 30 mg doses of CAB. Safety evaluations and serial PK samples will be collected during each treatment period. A follow-up visit will occur 10 - 14 days after the last dose of study drug. Treatment period doses will be separated by a 14 day washout. Participation in this study will be approximately 12 weeks.

Clinical Trial Conditions for CABOTEGRAVIR SODIUM

Condition Name

Condition Name for CABOTEGRAVIR SODIUM
Intervention	Trials
Infection, Human Immunodeficiency Virus	1

Condition MeSH

Condition MeSH for CABOTEGRAVIR SODIUM
Intervention	Trials
Immunologic Deficiency Syndromes	1
HIV Infections	1
Acquired Immunodeficiency Syndrome	1

Clinical Trial Locations for CABOTEGRAVIR SODIUM

Trials by Country

Trials by Country for CABOTEGRAVIR SODIUM
Location	Trials
United States	1

Trials by US State

Trials by US State for CABOTEGRAVIR SODIUM
Location	Trials
Kansas	1

Clinical Trial Progress for CABOTEGRAVIR SODIUM

Clinical Trial Phase

Clinical Trial Phase for CABOTEGRAVIR SODIUM
Clinical Trial Phase	Trials
Phase 1	1

Clinical Trial Status

Clinical Trial Status for CABOTEGRAVIR SODIUM
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for CABOTEGRAVIR SODIUM

Sponsor Name

Sponsor Name for CABOTEGRAVIR SODIUM
Sponsor	Trials
ViiV Healthcare	1

Sponsor Type

Sponsor Type for CABOTEGRAVIR SODIUM
Sponsor	Trials
Industry	1